A3AR agonists already demonstrating good safety profiles in the clinical trials and the US Food and Drug Administration (FDA) and the European Medicines Agency have granted fast track designation to an A3AR agonist for the treatment of hepatocellular carcinoma [21]. The gene discussed is ADORA3; the disease is hepatocellular carcinoma.